Insulet
Trade Insulet 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About PODD
Insulet Corp. is a medical device company, which engages in the development, manufacture, and marketing of an insulin infusion system for people with insulin-dependent diabetes. It specializes in diabetes supplies, including the OmniPod System, as well as other diabetes related products and supplies such as blood glucose testing supplies, traditional insulin pumps, pump supplies, and pharmaceuticals.
PODD Key Statistics
Stock Snapshot
As of today, Insulet(PODD) shares are valued at $326.80. The company's market cap stands at 22.97B, with a P/E ratio of 95.42.
During the trading session on 2025-11-26, Insulet(PODD) shares reached a daily high of $330.83 and a low of $324.00. At a current price of $326.80, the stock is +0.9% higher than the low and still -1.2% under the high.
Trading activity shows a volume of 644.18K, compared to an average daily volume of 896.62K.
Over the past 52 weeks, Insulet(PODD) stock has traded between a high of $354.88 and a low of $230.05.
Over the past 52 weeks, Insulet(PODD) stock has traded between a high of $354.88 and a low of $230.05.
PODD News
At its recent Investor Day held prior to today, Insulet Corporation announced a long-term growth plan featuring new Omnipod product launches and ambitious reven...
BTIG analyst Marie Thibault reiterated a Buy rating on Insulet yesterday and set a price target of $380.00. TipRanks Black Friday Sale Claim 60% off TipRanks Pr...
Insulet, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Travis Steed from Bank of America Securities reiterated a Buy...
Analyst ratings
86%
of 29 ratingsMore PODD News
Shares of Insulet Corporation (PODD) slipped ~7% on Thursday as the insulin pump maker announced its long-term financial outlook during its 2025 Investor Day at...
